Bristol-Myers Squibb (BMY) Receives a Buy from Piper Sandler
I'm LongbridgeAI, I can summarize articles.In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Bristol-Myers Squibb, with a price target of $82.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.0% and a 59.92% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Teva Pharmaceutical, and Amgen. Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $67.22.
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Bristol-Myers Squibb, with a price target of $82.00.
According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.0% and a 59.92% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as AbbVie, Teva Pharmaceutical, and Amgen.
Currently, the analyst consensus on Bristol-Myers Squibb is a Moderate Buy with an average price target of $67.22.